Kjell Öberg

A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires

van Leeuwaarde, Rachel S.; Gonzalez-Clavijo, Angelica M.; Pracht, Marc; Emelianova, Galina et al.

Ingår i Journal of Clinical Medicine, 2022

• DOI för A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires
• Ladda ner fulltext (pdf) av A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires

ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours

Dromain, Clarisse; Vullierme, Marie-Pierre; Hicks, Rodney J.; Prasad, Vikas et al.

Ingår i Journal of neuroendocrinology, 2022

• DOI för ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours
• Ladda ner fulltext (pdf) av ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study

Hörsch, Dieter; Anthony, Lowell; Gross, David J.; Valle, Juan et al.

Ingår i Neuroendocrinology, s. 298-309, 2022

• DOI för Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study
• Ladda ner fulltext (pdf) av Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study

Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3(rd)-line treatment

Lamarca, Angela; Cives, Mauro; de Mestier, Louis; Crona, Joakim et al.

Ingår i World Journal of Gastroenterology, s. 976-989, 2021

• DOI för Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3(rd)-line treatment

Cardiac Imaging in Carcinoid Heart Disease

Baron, Tomasz; Bergsten, Johannes; Albåge, Anders; Lundin, Lennart et al.

Ingår i JACC Cardiovascular Imaging, s. 2240-2253, 2021

• DOI för Cardiac Imaging in Carcinoid Heart Disease

A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires

van Leeuwaarde, Rachel S.; Gonzalez-Clavijo, Angelica M.; Pracht, Marc; Emelianova, Galina et al.

Ingår i Journal of Clinical Medicine, 2022

• DOI för A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires
• Ladda ner fulltext (pdf) av A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires

ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours

Dromain, Clarisse; Vullierme, Marie-Pierre; Hicks, Rodney J.; Prasad, Vikas et al.

Ingår i Journal of neuroendocrinology, 2022

• DOI för ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours
• Ladda ner fulltext (pdf) av ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study

Hörsch, Dieter; Anthony, Lowell; Gross, David J.; Valle, Juan et al.

Ingår i Neuroendocrinology, s. 298-309, 2022

• DOI för Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study
• Ladda ner fulltext (pdf) av Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study

Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3(rd)-line treatment

Lamarca, Angela; Cives, Mauro; de Mestier, Louis; Crona, Joakim et al.

Ingår i World Journal of Gastroenterology, s. 976-989, 2021

• DOI för Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3(rd)-line treatment

Cardiac Imaging in Carcinoid Heart Disease

Baron, Tomasz; Bergsten, Johannes; Albåge, Anders; Lundin, Lennart et al.

Ingår i JACC Cardiovascular Imaging, s. 2240-2253, 2021

• DOI för Cardiac Imaging in Carcinoid Heart Disease

A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility

Modlin, I. M.; Kidd, M.; Falconi, M.; Filosso, P. L. et al.

Ingår i Annals of Oncology, s. 1425-1433, 2021

• DOI för A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility

Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest)

Modlin, Irvin M.; Kidd, Mark; Öberg, Kjell; Falconi, Massimo et al.

Ingår i Annals of Surgical Oncology, s. 7506-7517, 2021

• DOI för Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE

Strosberg, Jonathan R.; Srirajaskanthan, Rajaventhan; El-Haddad, Ghassan; Wolin, Edward M. et al.

Ingår i Journal of Nuclear Medicine, s. 1712-1718, 2021

• DOI för Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE
• Ladda ner fulltext (pdf) av Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.

Tholander, Bengt; Koliadi, Anthoula; Botling, Johan; Dahlstrand, Hanna et al.

Ingår i Upsala Journal of Medical Sciences, s. 325-329, 2020

• DOI för Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Lu-177-Dotatate: an analysis of the NETTER-1 study

Strosberg, Jonathan; Kunz, Pamela L.; Hendifar, Andrew; Yao, James et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, s. 2372-2382, 2020

• DOI för Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Lu-177-Dotatate: an analysis of the NETTER-1 study
• Ladda ner fulltext (pdf) av Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Lu-177-Dotatate: an analysis of the NETTER-1 study

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pavel, M.; Öberg, Kjell; Falconi, M.; Krenning, E. P. et al.

Ingår i Annals of Oncology, s. 844-860, 2020

• DOI för Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Neuroendocrine Neoplasms of the Small Bowel and Pancreas

Clift, Ashley Kieran; Kidd, Mark; Bodei, Lisa; Toumpanakis, Christos et al.

Ingår i Neuroendocrinology, s. 444-476, 2020

• DOI för Neuroendocrine Neoplasms of the Small Bowel and Pancreas

Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms

Matar, Somer; Malczewska, Anna; Öberg, Kjell; Bodei, Lisa et al.

Ingår i Neuroendocrinology, s. 185-197, 2020

• DOI för Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms

Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome

Hudgens, Stacie; Ramage, John; Kulke, Matthew; Bergsland, Emily et al.

Ingår i Journal of Patient-Reported Outcomes, 2019

• DOI för Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome
• Ladda ner fulltext (pdf) av Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome

NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging

Malczewska, Anna; Witkowska, Magdalena; Makulik, Karolina; Bocian, Agnes et al.

Ingår i Endocrine Connections, s. 442-453, 2019

• DOI för NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging
• Ladda ner fulltext (pdf) av NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging

Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome

Anthony, Lowell B.; Kulke, Matthew H.; Caplin, Martyn E.; Bergsland, Emily et al.

Ingår i The Oncologist, 2019

• DOI för Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome

NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease

Malczewska, Anna; Öberg, Kjell; Bodei, Lisa; Aslanian, Harry et al.

Ingår i Neuroendocrinology, s. 219-231, 2019

• DOI för NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease

Impact of baseline liver tumor burden on treatment outcomes with 177Lu-Dotatate in the Netter-1 study

Strosberg, J.; Wolin, E.; Yao, J.; Kulke, M. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2018

Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms

Grimaldi, Franco; Fazio, Nicola; Attanasio, Roberto; Frasoldati, Andrea et al.

Ingår i Endocrine, Metabolic & Immune Disorders - Drug Targets, s. 419-449, 2018

• DOI för Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms

Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel Immunohistochemical Markers

Daskalakis, Kosmas; Kaltsas, Gregory; Öberg, Kjell; Tsolakis, Apostolos V.

Ingår i Neuroendocrinology, s. 355-365, 2018

• DOI för Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel Immunohistochemical Markers

IFN-alpha in advanced well-differentiated neuroendocrine tumors: the neglected drug?

Amoroso, Vito; Pavel, Marianne; Claps, Melanie; Roca, Elisa et al.

Ingår i Future Oncology, s. 897-899, 2018

• DOI för IFN-alpha in advanced well-differentiated neuroendocrine tumors: the neglected drug?

The Genesis of the Neuroendocrine Tumors Concept: From Oberndorfer to 2018

Öberg, Kjell

Ingår i Endocrinology and metabolism clinics of North America (Print), s. 711-731, 2018

• DOI för The Genesis of the Neuroendocrine Tumors Concept: From Oberndorfer to 2018

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-177-Dotatate in the Phase III NETTER-1 Trial

Strosberg, Jonathan; Wolin, Edward; Chasen, Beth; Kulke, Matthew et al.

Ingår i Journal of Clinical Oncology, s. 2578-2584, 2018

• DOI för Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-177-Dotatate in the Phase III NETTER-1 Trial

Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Weickert, Martin O.; Kaltsas, Gregory; Hörsch, Dieter; Lapuerta, Pablo et al.

Ingår i Clinical Therapeutics, s. 952-962, 2018

• DOI för Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome
• Ladda ner fulltext (pdf) av Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?

Van Leeuwaarde, R.; Spada, F.; Cheung, W.; Gonzalez-Clavijo, A. et al.

Ingår i Neuroendocrinology, s. 122-122, 2018

• DOI för Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?

Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors

Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M. et al.

Ingår i Neuroendocrinology, s. 260-260, 2018

• DOI för Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors

Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Weickert, Martin O.; Kaltsas, Gregory; Hörsch, Dieter; Lapuerta, Pablo et al.

Ingår i Pancreas, s. 357-358, 2018

• DOI för Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period

Hörsch, Dieter; Kulke, Matthew H.; Caplin, Martyn E.; Anthony, Lowell B. et al.

Ingår i Pancreas, s. 341-342, 2018

• DOI för Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period

QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors

Strosberg, Jonathan; Wolin, Edward; Chasen, Beth; Kulke, Matthew et al.

Ingår i Pancreas, s. 355-355, 2018

• DOI för QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors

Association of a Prophylactic surgical approach to Stage IV Small Intestinal Neuroendocrine Tumors with Survival.

Daskalakis, Kosmas; Karakatsanis, Andreas; Hessman, Ola; Stuart, Heather C. et al.

Ingår i JAMA Oncology, s. 183-189, 2018

• DOI för Association of a Prophylactic surgical approach to Stage IV Small Intestinal Neuroendocrine Tumors with Survival.

Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome

Pavel, M. E.; Gable, J.; Kulke, M. H.; Bergsland, E. et al.

Ingår i Oncology Research and Treatment, s. 238-238, 2017

Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs

Singh, Simron; Granberg, Dan; Wolin, Edward; Warner, Richard et al.

Ingår i Journal of global oncology, s. 43-53, 2017

• DOI för Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs
• Ladda ner fulltext (pdf) av Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs

Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer

Yu, Di; Leja, Justyna; Loskog, Angelica S.; Hellman, Per et al.

Ingår i Neuroendocrinology, s. 54-66, 2017

• DOI för Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer

Quality of Life Improvements in Patients with progressive Midgut Neuroendocrine Tumors: the NETTER-1 Phase III Trial

Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2017

Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period

Hoersch, D.; Kulke, M. H.; Caplin, M.; Anthony, L. et al.

Ingår i Annals of Oncology, 2017

Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trial

Strosberg, J.; Wolin, E. M.; Chasen, B.; Kulke, M. H. et al.

Ingår i Annals of Oncology, 2017

Long-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl

Lapuerta, P.; Kulke, M. H.; Caplin, M.; Bergsland, E. et al.

Ingår i Annals of Oncology, 2017

Impact of Concomitant Medication on Efficacy of Telotristat Ethyl - A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome

Anthony, L.; Kulke, M. H.; Hoersch, D.; Bergsland, E. et al.

Ingår i Neuroendocrinology, s. 212-212, 2017

NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors

Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M. H. et al.

Ingår i Neuroendocrinology, s. 257-257, 2017

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

Ferolla, Piero; Brizzi, Maria Pia; Meyer, Tim; Mansoor, Wasat et al.

Ingår i The Lancet Oncology, s. 1652-1664, 2017

• DOI för Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl

Anthony, Lowell; Ervin, Claire; Lapuerta, Pablo; Kulke, Matthew H. et al.

Ingår i Clinical Therapeutics, s. 2158-2168, 2017

• DOI för Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl
• Ladda ner fulltext (pdf) av Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl

Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors

Strosberg, J.; El-Haddad, G.; Wolin, E.; Hendifar, A. et al.

Ingår i New England Journal of Medicine, s. 125-135, 2017

• DOI för Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

Öberg, Kjell; Couvelard, Anne; Delle Fave, Gianfranco; Gross, David et al.

Ingår i Neuroendocrinology, s. 201-211, 2017

• DOI för ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Pavel, M. E.; Baudin, E.; Öberg, Kjell; Hainsworth, J. D. et al.

Ingår i Annals of Oncology, s. 1569-1575, 2017

• DOI för Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Efficacy and Safety Results of Telotristat Ethyl in Patients With Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial

Pavel, Marianne; Gross, David; Benavent, Marta; Caplin, Martyn et al.

Ingår i Pancreas, s. 434-435, 2017

• DOI för Efficacy and Safety Results of Telotristat Ethyl in Patients With Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Kulke, Matthew H.; Hoersch, Dieter; Caplin, Martyn E.; Anthony, Lowell B. et al.

Ingår i Journal of Clinical Oncology, s. 14-23, 2017

• DOI för Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study

Ferolla, P.; Brizzi, M. P.; Meyer, T.; Mansoor, W. et al.

Ingår i Annals of Oncology, 2016

• DOI för Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study

NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis

Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M. et al.

Ingår i Annals of Oncology, 2016

• DOI för NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis

Assessing Treatment Benefit of Telotristat Etiprate in Patients with Carcinoid Syndrome: Patient Exit Interviews

Anthony, Lowell; Hoersch, Dieter; Ervin, Claire; Kulke, Matthew H. et al.

Ingår i Pancreas, s. 470-470, 2016

Telotristat Etiprate Shows Benefit in Treating Patients With Carcinoid Syndrome That is Inadequately Controlled by Somatostatin Analog Therapy in the Phase 3 TELESTAR Clinical Trial

Kulke, Matthew H.; Hoersch, Dieter; Caplin, Martyn; Anthony, Lowell et al.

Ingår i Pancreas, s. 478-478, 2016

NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE: Efficacy and Safety Results

Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M. et al.

Ingår i Neuroendocrinology, s. 95-95, 2016

miR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease

Giandomenico, V; Li, Su-Chen; Lind, Thomas; Boccherini, M. et al.

Ingår i Neuroendocrinology, s. 115-115, 2016

Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog Therapy: Analysis of the Ongoing TELESTAR Extension Period

Hrsch, D.; Kulke, M.; Caplin, M.; Anthony, L. et al.

Ingår i Neuroendocrinology, s. 88-88, 2016

Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome

Pavel, M.; Hoersch, D.; Anthony, L.; Ervin, C. et al.

Ingår i Neuroendocrinology, s. 89-89, 2016

A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

Öberg, Kjell; Krenning, Eric; Sundin, Anders; Bodei, Lisa et al.

Ingår i Endocrine Connections, s. 174-187, 2016

• DOI för A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
• Ladda ner fulltext (pdf) av A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

Dittrich, Christian; Kosty, Michael; Jezdic, Svetlana; Pyle, Doug et al.

Ingår i ESMO Open, 2016

• DOI för ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
• Ladda ner fulltext (pdf) av ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results

Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M. et al.

Ingår i European Journal of Nuclear Medicine and Molecular Imaging, 2016

ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas)

Pape, U. -F; Niederle, B.; Costa, F.; Gross, D. et al.

Ingår i Neuroendocrinology, s. 144-152, 2016

• DOI för ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas)

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

Niederle, B.; Pape, U. -F; Costa, F.; Gross, D. et al.

Ingår i Neuroendocrinology, s. 125-138, 2016

• DOI för ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study

Yao, James C.; Pavel, Marianne; Lombard-Bohas, Catherine; Van Cutsem, Eric et al.

Ingår i Journal of Clinical Oncology, s. 3906-3913, 2016

• DOI för Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

Pavel, M.; O'Toole, D.; Costa, F.; Capdevila, J. et al.

Ingår i Neuroendocrinology, s. 172-185, 2016

• DOI för ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate

Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M. et al.

Ingår i Annals of Oncology, s. 121-121, 2016

NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate

Strosberg, Jonathan R.; Wolin, Edward M.; Chasen, Beth; Kulke, Matthew H. et al.

Ingår i Journal of Clinical Oncology, 2016

177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors: Results of the Phase III NETTER-1 Trial

Strosberg, Jonathan; Wolin, Edward; Chasen, Beth; Kulke, Matthew et al.

Ingår i Pancreas, s. 483-483, 2016

• DOI för 177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors: Results of the Phase III NETTER-1 Trial

Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome

Kulke, M.; Hoersch, D.; Caplin, M.; Anthony, L. et al.

Ingår i Annals of Oncology, 2016

• DOI för Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome

Universal everolimus for malignant neuroendocrine tumours?

Öberg, Kjell

Ingår i The Lancet, s. 924-926, 2016

• DOI för Universal everolimus for malignant neuroendocrine tumours?

Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET): A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data

Strosberg, Jonathan R.; Yao, James C.; Bajetta, Emilio; Aout, Mounir et al.

Ingår i Pancreas, s. 359-359, 2015

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Wolin, Edward M.; Jarzab, Barbara; Eriksson, Barbro; Walter, Thomas et al.

Ingår i Drug Design, Development and Therapy, s. 5075-5086, 2015

• DOI för Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
• Ladda ner fulltext (pdf) av Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role

Kanakis, George; Grimelius, Lars; Spathis, Athanasios; Tringidou, Rodoula et al.

Ingår i Neuroendocrinology, s. 211-222, 2015

• DOI för Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role

Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs

Li, Su-Chen; Khan, Mohid; Caplin, Martyn; Meyer, Tim et al.

Ingår i PLOS ONE, 2015

• DOI för Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs
• Ladda ner fulltext (pdf) av Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs

Functional role of miR-196a in neuroendocrine tumor cells

Shi, Hao; Li, Su-Chen; Khan, Mohid; Caplin, Martyn et al.

Ingår i Neuroendocrinology, s. 87-87, 2015

• DOI för Functional role of miR-196a in neuroendocrine tumor cells

Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial

Anthony, Lowell B.; Pavel, Marianne E.; Hainsworth, John D.; Kvols, Larry K. et al.

Ingår i Neuroendocrinology, s. 18-25, 2015

• DOI för Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial

Roles of miR-196a on gene regulation of neuroendocrine tumor cells

Li, Su-Chen; Shi, Hao; Khan, Mohid; Caplin, Martyn et al.

Ingår i Molecular and Cellular Endocrinology, s. 131-139, 2015

• DOI för Roles of miR-196a on gene regulation of neuroendocrine tumor cells

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

Caplin, M. E.; Baudin, E.; Ferolla, P.; Filosso, P. et al.

Ingår i Annals of Oncology, s. 1604-1620, 2015

• DOI för Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial

Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M. et al.

Ingår i European Journal of Cancer, 2015

Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects

Koumarianou, Anna; Kaltsas, Gregory; Kulke, Matthew H.; Öberg, Kjell et al.

Ingår i Neuroendocrinology, s. 274-288, 2015

• DOI för Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects

Multidisciplinary Team (MDT) in Neuroendocrine Tumor (NET) Management: Results from the First Global NET Patient (pt) Survey - A Collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

Oberg, Kjell; Leyden, J.; Sissons, M.; Kolarova, T. et al.

Ingår i Neuroendocrinology, s. 159-160, 2015

• DOI för Multidisciplinary Team (MDT) in Neuroendocrine Tumor (NET) Management: Results from the First Global NET Patient (pt) Survey - A Collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)

Kulke, M. H.; Hoersch, D.; Caplin, M.; Anthony, L. et al.

Ingår i European Journal of Cancer, 2015

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis

Strosberg, Jonathan R.; Yao, James C.; Bajetta, Emilio; Aout, Mounir et al.

Ingår i Endocrine-Related Cancer, s. 933-940, 2015

• DOI för Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis
• Ladda ner fulltext (pdf) av Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis

Everolimus Plus Octreotide Long-Acting Repeatable (LAR) for the Treatment of Advanced Neuroendocrine Tumors (NET) Associated with Carcinoid Syndrome: Updated Overall Survival Results from RADIANT-2 Study

Yao, James C.; Öberg, Kjell E.; Hainsworth, John D.; Lam, Du et al.

Ingår i Pancreas, s. 508-509, 2014

A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs

Wolin, Edward M.; Jarzab, Barbara; Eriksson, Barbro; Walter, Thomas et al.

Ingår i Pancreas, s. 508-508, 2014

Treatment of high-grade neuroendocrine tumors beyond platinum/etoposide

Öberg, Kjell

Ingår i Oncology Research and Treatment, s. 297-298, 2014

Indication for Liver Transplantation in Young Patients with Small Intestinal NETs Is Rare?

Norlén, Olov; Daskalakis, Kosmas; Öberg, Kjell; Åkerström, Göran et al.

Ingår i World Journal of Surgery, s. 742-747, 2014

• DOI för Indication for Liver Transplantation in Young Patients with Small Intestinal NETs Is Rare?

Neuroendocrine Tumor Biomarkers: Current Status and Perspectives

Modlin, Irvin M.; Öberg, Kjell; Taylor, Andrew; Drozdov, Ignat et al.

Ingår i Neuroendocrinology, s. 265-277, 2014

• DOI för Neuroendocrine Tumor Biomarkers: Current Status and Perspectives

Circulating microRNA detection in small intestinal neuroendocrine tumor patients treated with somatostatin analogs

Li, Su-Chen; Khan, Mohid; Caplin, Martyn; Meyer, Tim et al.

2014

Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors

Tamagno, G.; Crespo, G.; Fierro Maya, E.; Fossmark, R. et al.

Ingår i Neuroendocrinology, s. 280-281, 2014

Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET): A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS)

Strosberg, J. R.; Yao, J. C.; Bajetta, E.; Aout, M. et al.

Ingår i Neuroendocrinology, s. 274-274, 2014

MicroRNA Expression in Serum of Small Intestine Neuroendocrine Tumor Patients and miR-196a Biological Function in Neuroendocrine Tumor Cells

Li, Su-Chen; Khan, M. S.; Caplin, M.; Öberg, Kjell et al.

Ingår i Neuroendocrinology, s. 228-228, 2014

Combination of Cross-Sectional and Molecular Imaging Studies in the Localization of Gastroenteropancreatic Neuroendocrine Tumors

Toumpanakis, Christos; Kim, Michelle K.; Rinke, Anja; Bergestuen, Deidi S. et al.

Ingår i Neuroendocrinology, s. 63-74, 2014

• DOI för Combination of Cross-Sectional and Molecular Imaging Studies in the Localization of Gastroenteropancreatic Neuroendocrine Tumors

Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms

Grimaldi, Franco; Fazio, Nicola; Attanasio, Roberto; Frasoldati, Andrea et al.

Ingår i Journal of Endocrinological Investigation, s. 875-909, 2014

• DOI för Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms

Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET): A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with updated survival data

Strosberg, Jonathan R.; Yao, James C.; Bajetta, Emilio; Aout, Mounir et al.

Ingår i Journal of Clinical Oncology, 2014

Identification of Candidate Serum Proteins for Classifying Well-Differentiated Small Intestinal Neuroendocrine Tumors

Darmanis, Spyros; Cui, Tao; Drobin, Kimi; Li, Su-Chen et al.

Ingår i PLOS ONE, 2013

• DOI för Identification of Candidate Serum Proteins for Classifying Well-Differentiated Small Intestinal Neuroendocrine Tumors
• Ladda ner fulltext (pdf) av Identification of Candidate Serum Proteins for Classifying Well-Differentiated Small Intestinal Neuroendocrine Tumors

Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations

Liu, Eric; Marincola, Paula; Öberg, Kjell

Ingår i Therapeutic Advances in Gastroenterology, s. 412-419, 2013

• DOI för Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations

Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas

Cui, Tao; Tsolakis, Apostolos V; Li, Su-Chen; Cunningham, Janet L et al.

Ingår i European Journal of Endocrinology, s. 253-261, 2013

• DOI för Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas

Treatment, prognostic markers and survival in thymic neuroendocrine tumours: A study from a single tertiary referral centre

Crona, Joakim; Björklund, Peyman; Welin, Staffan; Kozlovacki, Gordana et al.

Ingår i Lung Cancer, s. 289-293, 2013

• DOI för Treatment, prognostic markers and survival in thymic neuroendocrine tumours: A study from a single tertiary referral centre

Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids

Crona, Joakim; Fanola, Irina; Lindholm, Daniel P.; Antonodimitrakis, Pantelis et al.

Ingår i Neuroendocrinology, s. 151-155, 2013

• DOI för Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids

Olfactory Receptor 51E1 as a Novel Target for Diagnosis in Somatostatin Receptor Negative Lung Carcinoids

Giandomenico, Valeria; Cui, Tao; Grimelius, Lars; Öberg, Kjell et al.

Ingår i Journal of Molecular Endocrinology, s. 277-286, 2013

• DOI för Olfactory Receptor 51E1 as a Novel Target for Diagnosis in Somatostatin Receptor Negative Lung Carcinoids

Everolimus plus octreotide long-acting release (LAR) for the treatment of advanced neuroendocrine tumors (NET) associated with carcinoid syndrome (RADIANT-2): Updated overall survival results

Pavel, M.; Öberg, Kjell E.; Hainsworth, J. D.; Lam, D. et al.

Ingår i European Journal of Cancer, 2013

Microarray Immunoassay Development to Specifically Detect Autoantibodies in Small Intestine Neuroendocrine Tumor (SI-NET) Patients

Bergström, Joakim; Cui, Tao; Li, Su-Chen; Öberg, Kjell et al.

Ingår i Pancreas, s. 369-370, 2013

B12Global MicroRNA Profiling of Small Intestine Neuroendocrine Tumors (SI-NETs) and Establishment of a Method to Study Serum MicroRNA Expression From the Same Tumors

Li, Su-Chen; Martijn, Cecile; Essaghir, Ahmed; Lloyd, Ricardo V. et al.

Ingår i Pancreas, s. 377-377, 2013

Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis of Small Intestine Neuroendocrine Tumors

Cui, Tao; Tsolakis, Apostolos V.; Cunningham, Janet; Li, Su-Chen et al.

Ingår i Pancreas, s. 373-373, 2013

Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors.

Li, Su-Chen; Essaghir, Ahmed; Martijn, Cécile; Lloyd, Ricardo V et al.

Ingår i Modern Pathology, s. 685-696, 2013

• DOI för Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors.

Improving the Diagnosis and Management of Neuroendocrine Tumors: Utilizing New Advances in Biomarker and Molecular Imaging Science

Giandomenico, Valeria; Modlin, Irvin M.; Pontén, Fredrik; Nilsson, Mats et al.

Ingår i Neuroendocrinology, s. 16-30, 2013

• DOI för Improving the Diagnosis and Management of Neuroendocrine Tumors: Utilizing New Advances in Biomarker and Molecular Imaging Science

Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy

Öberg, Kjell

Ingår i Nature reviews. Endocrinology, s. 70-72, 2013

• DOI för Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy

Gallium-68 somatostatin receptor PET/CT: Is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?

Öberg, Kjell

Ingår i Endocrine, s. 3-4, 2012

• DOI för Gallium-68 somatostatin receptor PET/CT: Is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?

The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells

Li, Su-Chen; Martijn, Cécile; Cui, Tao; Essaghir, Ahmed et al.

Ingår i PLOS ONE, 2012

• DOI för The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
• Ladda ner fulltext (pdf) av The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells

Long-Term Results of Surgery for Small Intestinal Neuroendocrine Tumors at a Tertiary Referral Center

Norlén, Olov; Stålberg, Peter; Öberg, Kjell; Eriksson, John et al.

Ingår i World Journal of Surgery, s. 1419-1431, 2012

• DOI för Long-Term Results of Surgery for Small Intestinal Neuroendocrine Tumors at a Tertiary Referral Center

Severe systemic vasoconstriction starting with acute limb ischemia leading to death in a patient with well-differentiated pulmonary neuroendocrine carcinoma: a new paraneoplastic syndrome?

Karadeniz, Cemile; Köse, Fatih; Abali, Hüseyin; Sümbül, Ahmet Taner et al.

Ingår i Acta Oncologica, s. 124-127, 2012

• DOI för Severe systemic vasoconstriction starting with acute limb ischemia leading to death in a patient with well-differentiated pulmonary neuroendocrine carcinoma: a new paraneoplastic syndrome?

Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Öberg, Kjell; Hellman, Per; Ferolla, P.; Papotti, M.

Ingår i Annals of Oncology, 2012

• DOI för Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Öberg, Kjell; Knigge, U.; Kwekkeboom, D.; Perren, A.

Ingår i Annals of Oncology, 2012

• DOI för Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Olfactory receptor 51E1 is a potential novel tissue biomarker for the diagnosis and prognosis of small intestine neuroendocrine tumors

Cui, Tao; Tsolakis, Apostolos V.; Cunningham, Janet; Li, Su-Chen et al.

Ingår i Regulatory Peptides, 2012

• DOI för Olfactory receptor 51E1 is a potential novel tissue biomarker for the diagnosis and prognosis of small intestine neuroendocrine tumors

Ramsete: a single-arm, multicenter, single-stage phase ii trial of rad001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in europe: analysis by tumor origin

Pavel, M.; Wiedenmann, B.; Capdevila, J.; Valle, J. W. et al.

Ingår i Annals of Oncology, s. 377-377, 2012

Implications for clinical practice and trial design

Öberg, Kjell

Ingår i Annals of Oncology, s. 47-48, 2012

The Management of Neuroendocrine Tumours: Current and Future Medical Therapy Options

Öberg, Kjell E

Ingår i Clinical Oncology, s. 282-293, 2012

• DOI för The Management of Neuroendocrine Tumours: Current and Future Medical Therapy Options

Unusual Complication of a Pancreatic Neuroendocrine Tumor Presenting with Malignant Hypercalcemia

Kanakis, G.; Kaltsas, G.; Granberg, Dan; Grimelius, Lars et al.

Ingår i Journal of Clinical Endocrinology and Metabolism, 2012

• DOI för Unusual Complication of a Pancreatic Neuroendocrine Tumor Presenting with Malignant Hypercalcemia

ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

Pavel, Marianne; Baudin, Eric; Couvelard, Anne; Krenning, Eric et al.

Ingår i Neuroendocrinology, s. 157-176, 2012

• DOI för ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

Biotherapies for GEP-NETs

Öberg, Kjell

Ingår i Baillière's Best Practice & Research, s. 833-841, 2012

• DOI för Biotherapies for GEP-NETs

PET-Guided Surgery: High Correlation between Positron Emission Tomography with ¹¹C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine Tumours

Örlefors, Håkan; Sundin, Anders; Eriksson, Barbro; Skogseid, Britt et al.

Ingår i Cancers, s. 100-112, 2012

• DOI för PET-Guided Surgery: High Correlation between Positron Emission Tomography with ¹¹C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine Tumours

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

Kvols, Larry K; Öberg, Kjell E; O'Dorisio, Thomas M; Mohideen, Pharis et al.

Ingår i Endocrine-related cancer, s. 657-66, 2012

• DOI för Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

The Cytotoxic Effect of Emetine and CGP-74514A Studied with the Hollow Fiber Model and ArrayScan Assay in Neuroendocrine Tumors In Vitro

Larsson, Dhana E.; Hassan, Saadia Bashir; Öberg, Kjell; Granberg, Dan

Ingår i ANTI-CANCER AGENT ME, s. 783-790, 2012

Gastric carcinoid in a patient infected with Helicobacter pylori: A new entity?

Antonodimitrakis, Pantelis; Tsolakis, Apostolos; Welin, Staffan; Kozlovacki, Gordana et al.

Ingår i World Journal of Gastroenterology, s. 3066-3068, 2011

• DOI för Gastric carcinoid in a patient infected with Helicobacter pylori: A new entity?

Neuroendocrine neoplasms

Schott, M; Öberg, Kjell

Ingår i Hormone and Metabolic Research, s. 823-824, 2011

• DOI för Neuroendocrine neoplasms

Everolimus for advanced pancreatic neuroendocrine tumors

Yao, James C.; Shah, Manisha H.; Ito, Tetsuhide; Bohas, Catherine Lombard et al.

Ingår i New England Journal of Medicine, s. 514-523, 2011

• DOI för Everolimus for advanced pancreatic neuroendocrine tumors

Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

Kulke, Matthew H.; Siu, Lillian L.; Tepper, Joel E.; Fisher, George et al.

Ingår i Journal of Clinical Oncology, s. 934-943, 2011

• DOI för Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy

Welin, Staffan; Sorbye, Halfdan; Sebjornsen, Sigrunn; Knappskog, Stian et al.

Ingår i Cancer, s. 4617-4622, 2011

• DOI för Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy

Neuroendocrine tumors A growing cancer field

Öberg, Kjell

Ingår i Revista Portuguesa de Cirurgia, s. 23-24, 2011

Management of Advanced Small Intestinal Neuroendocrine Tumors

Öberg, Kjell

Ingår i European journal of clinical & medical oncology, s. 64-70, 2011

Advances in Pancreatic Neuroendocrine Tumor Treatment REPLY

Yao, James C.; Ito, Tetsuhide; Öberg, Kjell

Ingår i New England Journal of Medicine, s. 1874-1875, 2011

Neuroendocrine tumors: recent progress in diagnosis and treatment

Öberg, Kjell

Ingår i Endocrine-Related Cancer, 2011

• DOI för Neuroendocrine tumors: recent progress in diagnosis and treatment

Management of neuroendocrine tumors: Current and future therapies

Öberg, Kjell

Ingår i Expert Reviews Endocrinology & Metabolism, s. 49-62, 2011

• DOI för Management of neuroendocrine tumors: Current and future therapies

Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells

Leja, Justyna; Yu, Di; Nilsson, Berith; Gedda, Lars et al.

Ingår i Gene Therapy, s. 1052-1062, 2011

• DOI för Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells

A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum

Walsh, Kyle M.; Choi, Murim; Öberg, Kjell E.; Kulke, Matthew H. et al.

Ingår i Endocrine-Related Cancer, s. 171-180, 2011

• DOI för A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum

Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours

Öberg, Kjell

Ingår i Endocrine-Related Cancer, 2011

• DOI för Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

Yao, James C; Pavel, Marianne; Phan, Alexandria T; Kulke, Matthew H et al.

Ingår i Journal of Clinical Endocrinology and Metabolism, s. 3741-3749, 2011

• DOI för Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Pavel, Marianne E; Hainsworth, John D; Baudin, Eric; Peeters, Marc et al.

Ingår i The Lancet, s. 2005-2012, 2011

• DOI för Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management.

Modlin, Irvin M; Moss, Steven F; Öberg, Kjell; Padbury, Robert et al.

Ingår i Medical Journal of Australia, s. 46-52, 2010

ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors

Kos-Kudła, Beata; O'Toole, Dermot; Falconi, Massimo; Gross, David et al.

Ingår i Neuroendocrinology, s. 341-350, 2010

• DOI för ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors

Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours

Janson, Eva Tiensuu; Sørbye, Halfdan; Welin, Staffan; Federspiel, Birgitte et al.

Ingår i Acta Oncologica, s. 740-756, 2010

• DOI för Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours

90Y-edotreotide for metastatic carcinoid refractory to octreotide

Bushnell, David L.; O'Dorisio, Thomas M.; O'Dorisio, M. Sue; Menda, Yusuf et al.

Ingår i Journal of Clinical Oncology, s. 1652-1659, 2010

• DOI för 90Y-edotreotide for metastatic carcinoid refractory to octreotide

NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)

Phan, Alexandria T; Öberg, Kjell; Choi, Junsung; Harrison, Lynn H et al.

Ingår i Pancreas, s. 784-798, 2010

• DOI för NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)

ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors

Pavel, Marianne; Grossman, Ashley; Arnold, Rudolf; Perren, Aurel et al.

Ingår i Neuroendocrinology, s. 326-332, 2010

• DOI för ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors

Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set

Klimstra, David S.; Modlin, Irvin R.; Adsay, N. Volkan; Chetty, Runjan et al.

Ingår i American Journal of Surgical Pathology, s. 300-313, 2010

• DOI för Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set

Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors

Cui, Tao; Hurtig, Monica; Elgue, Graciela; Li, Su-Chen et al.

Ingår i PLOS ONE, 2010

• DOI för Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors
• Ladda ner fulltext (pdf) av Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors

PROGNOSTIC AND PREDICTIVE VALUE OF CHROMOGRANIN A AND NEURON-SPECIFIC ENOLASE IN PATIENTS (PTS) WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET) TREATED WITH EVEROLIMUS

Öberg, Kjell; Kulke, M.; Pavel, M.; Phan, A. et al.

Ingår i Annals of Oncology, s. 266-266, 2010

Neuroendocrine tumors (NETs): historical overview and epidemiology

Öberg, Kjell

Ingår i Tumori (Milano), s. 797-801, 2010

Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR

Kvols, L.; Wiedenmann, B.; Öberg, Kjell; Mohideen, P. et al.

Ingår i Neuroendocrinology, s. 42-43, 2010

Rationale for Combining mTOR with other Targeted Agents in the Treatment of Neuroendocrine Tumors

Öberg, Kjell; Yao, J. C.

Ingår i Neuroendocrinology, s. 49-50, 2010

Neuroendocrine tumours

Öberg, Kjell

Ingår i Treatment Strategies - Oncology, s. 150-156, 2010

Neuroendokrine tumorer: ny diagnostik og terapi

Öberg, Kjell

Ingår i Ugeskrift for laeger, s. 2941-2941, 2010

The history and development of the gastroenteropancreatic endocrine axis

Liu, Eric H.; Öberg, Kjell

Ingår i Endocrinology and metabolism clinics of North America (Print), s. 697-711, 2010

• DOI för The history and development of the gastroenteropancreatic endocrine axis

The Cytotoxic Agents NSC-95397, Brefeldin A, Bortezomib and Sanguinarine Induce Apoptosis in Neuroendocrine Tumors In Vitro

Larsson, Dhana E.; Wickström, Malin; Hassan, Sadia; Öberg, Kjell et al.

Ingår i Anticancer Research, s. 149-156, 2010

Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability

Leja, Justyna; Nilsson, Berith; Yu, Di; Gustafson, Elisabet et al.

Ingår i PLOS ONE, 2010

• DOI för Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability

Gastrointestinal neuroendocrine tumors

Öberg, Kjell E.

Ingår i Annals of Oncology, 2010

• DOI för Gastrointestinal neuroendocrine tumors

Management of metastatic neuroendocrine tumors: Recent advances, Changing trends in the management of NET

Öberg, Kjell

Ingår i NET Journal Club, 2010

Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®)

Kindmark, Henrik; Janson, Eva Tiensuu; Gustavsson, Bengt; Eriksson, Camilla et al.

Ingår i Acta Oncologica, s. 100-101, 2010

• DOI för Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®)

Cancer: antitumor effects of octreotide LAR, a somatostatin analog

Öberg, Kjell

Ingår i Nature reviews. Endocrinology, s. 188-189, 2010

• DOI för Cancer: antitumor effects of octreotide LAR, a somatostatin analog

Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Öberg, Kjell; Åkerström, Göran; Rindi, G.; Jelic, S.

Ingår i Annals of Oncology, 2010

• DOI för Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Öberg, Kjell; Hellman, Per; Kwekkeboom, D.; Jelic, S.

Ingår i Annals of Oncology, 2010

• DOI för Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations

Sundin, Anders; Vullierme, Marie-Pierre; Kaltsas, Gregory; Plöckinger, Ursula et al.

Ingår i Neuroendocrinology, s. 167-183, 2009

• DOI för ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations

Is It Time to Widen the Use of Somatostatin Analogs in Neuroendocrine Tumors?

Öberg, Kjell E.

Ingår i Journal of Clinical Oncology, s. 4635-4636, 2009

• DOI för Is It Time to Widen the Use of Somatostatin Analogs in Neuroendocrine Tumors?

Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up

Öberg, Kjell; Jelic, S.

Ingår i Annals of Oncology, s. 147-149, 2009

• DOI för Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy

Öberg, Kjell; Ferone, Diego; Kaltsas, Gregory; Knigge, Ulrich-Peter et al.

Ingår i Neuroendocrinology, s. 209-213, 2009

• DOI för ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy

Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up

Öberg, Kjell; Jelic, S.

Ingår i Annals of Oncology, s. 150-153, 2009

• DOI för Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up

Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors)

Öberg, Kjell

Ingår i Current Opinion in Endocrinology, Diabetes and Obesity, s. 72-78, 2009

• DOI för Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors)

Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines

Larsson, Dhana E.; Hassan, Sadia; Larsson, Rolf; Öberg, Kjell et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 5-12, 2009

• DOI för Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines

Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue

Vikman, Sofia; Sommaggio, Roberta; De La Torre, Manuel; Öberg, Kjell et al.

Ingår i Acta Oncologica, s. 391-400, 2009

• DOI för Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
• Ladda ner fulltext (pdf) av Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue

Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas

Leja, Justyna; Essaghir, Ahmed; Essand, Magnus; Wester, Kenneth et al.

Ingår i Modern Pathology, s. 261-272, 2009

• DOI för Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas

Elevated Plasma Chromogranin A is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumours

Welin, Staffan; Stridsberg, Mats; Cunningham, Janet; Granberg, Dan et al.

Ingår i Neuroendocrinology, s. 302-307, 2009

• DOI för Elevated Plasma Chromogranin A is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumours

Selective internal radiation therapy in patients with carcinoid liver metastases

Granberg, Dan; Garske, Ulrike; Welin, Staffan; Kindmark, Henrik et al.

Ingår i Acta Oncologica, s. 1169-1171, 2008

• DOI för Selective internal radiation therapy in patients with carcinoid liver metastases

Management of neuroendocrine tumors: a meeting of experts from Latin America

Costa, F.; Domenichini, E.; Garavito, G.; Medrano, R. et al.

Ingår i Neuroendocrinology, s. 235-42, 2008

• DOI för Management of neuroendocrine tumors: a meeting of experts from Latin America

Poorly-differentiated endocrine carcinomas of midgut and hindgut origin

Ahlman, Håkan; Nilsson, Ola; McNicol, Anne M.; Ruszniewski, Philippe et al.

Ingår i Neuroendocrinology, s. 40-46, 2008

• DOI för Poorly-differentiated endocrine carcinomas of midgut and hindgut origin

CD8(+) T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients

Vikman, Sofia; Giandomenico, Valeria; Sommaggio, Roberta; Öberg, Kjell et al.

Ingår i Cancer Immunology and Immunotherapy, s. 399-409, 2008

• DOI för CD8(+) T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients

Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors

Fjällskog, Marie-Louise H.; Janson, Eva Tiensuu; Falkmer, Ursula G.; Vatn, Morten H. et al.

Ingår i Neuroendocrinology, s. 53-8, 2008

• DOI för Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors

Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report

Granberg, Dan; Jacobsson, Hans; Öberg, Kjell; Gustavsson, Jörgen et al.

Ingår i Digestion, s. 92-5, 2008

• DOI för Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report

Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Öberg, Kjell; Jelic, S

Ingår i Annals of Oncology, s. 104-105, 2008

• DOI för Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up

Öberg, Kjell; Jelic, S

Ingår i Annals of Oncology, s. 102-103, 2008

• DOI för Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up

Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years

Kindmark, Henrik; Sundin, Anders; Granberg, Dan; Dunder, Kristina et al.

Ingår i Medical Oncology, s. 330-337, 2007

• DOI för Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

Ekeblad, Sara; Sundin, Anders; Janson, Eva Tiensuu; Welin, Staffan et al.

Ingår i Clinical Cancer Research, s. 2986-2991, 2007

• DOI för Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors

Granberg, Dan; Eriksson, Lars-Gunnar; Welin, Staffan; Kindmark, Henrik et al.

Ingår i Acta Radiologica, s. 180-185, 2007

• DOI för Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors

Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues

Ludvigsen, Eva; Stridsberg, Mats; Taylor, John; Culler, Michael et al.

Ingår i Regulatory Peptides, s. 1-9, 2007

• DOI för Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues

Expression and function of vinculin in neuroendocrine tumors

Liu, Minghui; Öberg, Kjell; Zhou, Yinghua

Ingår i Tumor Biology, s. 196-204, 2007

• DOI för Expression and function of vinculin in neuroendocrine tumors

A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy

Leja, Justyna; Dzojic, Helena; Gustafson, Elisabet; Öberg, Kjell et al.

Ingår i Clinical Cancer Research, s. 2455-2462, 2007

• DOI för A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy

Somatostatin induces rapid contraction of neuroendocrine cells

Saras, Jan; Grönberg, Malin; Stridsberg, Mats; Öberg, Kjell E. et al.

Ingår i FEBS Letters, s. 1957-1962, 2007

• DOI för Somatostatin induces rapid contraction of neuroendocrine cells

Clinical management of neuroendocrine GEP-tumors - Current concepts and future directions

Öberg, Kjell

Ingår i Medicinska Istrazivanja: The Journal of the School of Medicine University of Belgrade, s. 24-27, 2007

Lungcarcinoider: inte så benigna som man trott

Granberg, Dan; Eriksson, Barbro; Janson, Eva Tiensuu; Öberg, Kjell et al.

Ingår i Läkartidningen, s. 2382-2384, 2006

Well-differentiated pancreatic tumor/carcinoma: insulinoma

de Herder, Wouter W.; Niederle, Bruno; Scoazec, Jean-Yves; Pauwels, Stanislas et al.

Ingår i Neuroendocrinology, s. 183-188, 2006

• DOI för Well-differentiated pancreatic tumor/carcinoma: insulinoma

Well-differentiated pancreatic nonfunctioning tumors/carcinoma

Falconi, Massimo; Plockinger, Ursula; Kwekkeboom, Dik J.; Manfredi, Riccardo et al.

Ingår i Neuroendocrinology, s. 196-211, 2006

• DOI för Well-differentiated pancreatic nonfunctioning tumors/carcinoma

Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines

Larsson, Dhana E.; Lövborg, Henrik; Rickardson, Linda; Larsson, Rolf et al.

Ingår i Anticancer Research, s. 4125-4129, 2006

Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies.

Tartaglia, Andreas; Portela-Gomes, Guida M; Oberg, Kjell; Vezzadini, undefined et al.

Ingår i Virchows Arch, s. 1-8, 2006

Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET).

Whitman, Hendricks H; Fishman, Elliot K; Oberg, Kjell; Wildman, Joseph M et al.

Ingår i Annals of the New York Academy of Sciences: Pheochromocytoma: First International Symposium, s. 59-78, 2006

Major Coverage of the advances in an expanding field

Oberg, Kjell

Ingår i Expert Review of Endocrinology & Metabolism, s. 1-2, 2006

Molecular imaging in diagnosis of neuroendocrine tumours.

Oberg, Kjell

Ingår i Lancet Oncol, s. 790-2, 2006

Expression of tyrosine kinase receptors in lung carcinoids.

Granberg, Dan; Wilander, Erik; Oberg, Kjell

Ingår i Tumour Biol, s. 153-7, 2006

Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography

Örlefors, Håkan; Sundin, Anders; Garske, Ulrike; Juhlin, Claes et al.

Ingår i Journal of Clinical Endocrinology and Metabolism, s. 3392-3400, 2005

• DOI för Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography

Developments in PET for the detection of endocrine tumours

Eriksson, Barbro; Örlefors, Håkan; Öberg, Kjell; Sundin, Anders et al.

Ingår i Baillière's Best Practice & Research. Clinical Endocrinology & Metabolism, s. 311-324, 2005

• DOI för Developments in PET for the detection of endocrine tumours

Gene expression in midgut carcinoid tumors: potential targets for immunotherapy

Vikman, Sofia; Essand, Magnus; Cunningham, Janet L.; de la Torre, Manuel et al.

Ingår i Acta Oncologica, s. 32-40, 2005

• DOI för Gene expression in midgut carcinoid tumors: potential targets for immunotherapy

Efficient human interferon-alpha gene transfer to neuroendocrine tumor cells with long-term and stable expression

Liu, Minghui; Kilarski, Witold W.; Gerwins, Pär; Öberg, Kjell et al.

Ingår i Neuroendocrinology, s. 264-73, 2005

• DOI för Efficient human interferon-alpha gene transfer to neuroendocrine tumor cells with long-term and stable expression

A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B.

Stridsberg, Mats; Eriksson, Barbro; Oberg, Kjell; Tiensuu Janson, Eva

Ingår i Regul Pept, s. 193-9, 2005

Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment.

Oberg, Kjell

Ingår i Curr Opin Oncol, s. 386-91, 2005

Business Briefing: European oncology review

Öberg, Kjell

Ingår i Business Briefing: European oncology review, 2005

Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's).

Oberg, Kjell

Ingår i Rocz Akad Med Bialymst, s. 62-8, 2005

Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours

Öberg, Kjell; Eriksson, Barbro

Ingår i Best Practice & Research Clinical Endocrinology & Metabolism, s. 265-276, 2005

• DOI för Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

Welin, Staffan; Janson, Eva Tiensuu; Sundin, Anders; Stridsberg, Mats et al.

Ingår i European Journal of Endocrinology, s. 107-112, 2004

• DOI för High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

PET in the diagnosis of neuroendocrine tumors

Sundin, Anders; Eriksson, Barbro; Bergström, Mats; Långström, Bengt et al.

Ingår i Annals of the New York Academy of Sciences, s. 246-257, 2004

• DOI för PET in the diagnosis of neuroendocrine tumors

Subtype Selective Interactions of Somatostatin and Somatostatin Analogs with sst1, sst2, and sst5 in BON-1 Cells.

Ludvigsen, Eva; Stridsberg, Mats; Taylor, John E; Culler, Michael D et al.

Ingår i Med Oncol, s. 285-96, 2004

A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A.

Stridsberg, Mats; Eriksson, Barbro; Oberg, Kjell; Tiensuu Janson, Eva

Ingår i Regul Pept, s. 219-27, 2004

Transfection of the multiple endocrine neoplastia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of junD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen and QM/Jif-1

Stålberg, Peter; Grimfjärd, Per; Santesson, Mårten; Zhou, Yinghua et al.

Ingår i The journal of clinical endocrinology & metabolism, s. 2326-2337, 2004

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types.

Oberg, Kjell; Astrup, Lone; Eriksson, Barbro; Falkmer, Sture E et al.

Ingår i Acta Oncol, s. 626-36, 2004

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.

Oberg, K; Kvols, L; Caplin, M; Delle Fave, G et al.

Ingår i Ann Oncol, s. 966-73, 2004

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview.

Öberg, Kjell; Astrup, Lone; Eriksson, Barbro; Falkmer, Sture E et al.

Ingår i Acta Oncol, s. 617-25, 2004

Management of neuroendocrine tumours.

Oberg, K

Ingår i Ann Oncol, 2004

Future aspects of somatostatin-receptor-mediated therapy.

Oberg, Kjell

Ingår i Neuroendocrinology, s. 57-61, 2004

Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors

Fjällskog, Marie-Louise; Ludvigsen, Eva; Stridsberg, Mats; Öberg, Kjell et al.

Ingår i Medical Oncology, s. 59-67, 2003

• DOI för Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors

Octreoscan in patients with bronchial carcinoid tumours.

Granberg, Dan; Sundin, Anders; Tiensuu Janson, Eva; Oberg, Kjell et al.

Ingår i Clin Endocrinol (Oxf), s. 793-9, 2003

Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue andintratumoral vessels in malignant endocrine pancreatic tumors.

Fjallskog, ML; Ludvigsen, E; Stridsberg, M; Oberg, K et al.

Ingår i Med Oncol, s. 59, 2003

Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

von Marschall, Zofia; Scholz, Arne; Cramer, Thorsten; Schäfer, Georgia et al.

Ingår i J Natl Cancer Inst, s. 437-48, 2003

Quality of life in patients with multiple endocrine neoplasia type 1 (MEN 1).

Berglund, G; Lidén, A; Hansson, M G; Oberg, K et al.

Ingår i Fam Cancer, s. 27-33, 2003

In Situ RNA-RNA Hybridization of Phospholipase C β3 Shows Lack of Expression in Neuroendocrine Tumours

Stålberg, Peter; Granberg, Dan; Carling, Tobias; Wilander, Erik et al.

Ingår i Anticancer Research, s. 2227-2232, 2003

Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.

Tiensuu Janson, E; Öberg, Kjell

Ingår i Cancer Chemother Biol Response Modif, s. 535-46, 2003

The role of PET in localization of neuroendocrine and adrenocortical tumors

Eriksson, Barbro; Bergström, Mats; Sundin, Anders; Juhlin, Claes et al.

Ingår i Annals of the New York Academy of Sciences, s. 159-169, 2002

• DOI för The role of PET in localization of neuroendocrine and adrenocortical tumors

'Satisfaction with care': associations with health-related quality of life and psychosocial function among Swedish patients with endocrine gastrointestinal tumours

Von Essen, Louise; Larsson, Gunnel; Öberg, Kjell; Sjödén, Per-Olow

Ingår i European Journal of Cancer Care, s. 91-99, 2002

• DOI för 'Satisfaction with care': associations with health-related quality of life and psychosocial function among Swedish patients with endocrine gastrointestinal tumours

Tractor-driving hours and their relation to self-reported low-back and hip symptoms.

Torén, A; Öberg, K; Lembke, B; Enlund, K et al.

Ingår i Appl Ergon, s. 139-46, 2002

Selection of chemotherapy by ex vivo assessment of tumor sensitivity tocytotoxic drugs: results of a clinical trial.

Berglund, A; Glimelius, B; Bergh, J; Brodin, O et al.

Ingår i Med Oncol, s. 151, 2002

Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs.

Fjällskog, M L; Sundin, A; Westlin, J E; Öberg, K et al.

Ingår i Med Oncol, s. 35-42, 2002

Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment.

Oberg, Kjell

Ingår i Curr Opin Oncol, s. 38-45, 2002

Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases.

Hellman, P; Lundstrom, T; Ohrvall, U; Eriksson, B et al.

Ingår i World J Surg, s. 991, 2002

Effects of interferon alpha on the expression of p21cip1/waf1 and cellcycle distribution in carcinoid tumors.

Zhou, Y; Wang, S; Yue, BG; Gobl, A et al.

Ingår i Cancer Invest, s. 348, 2002

Experience in treatment of metastatic pulmonary carcinoid tumors

Granberg, Dan; Eriksson, Barbro; Wilander, Erik; Grimfjärd, Per et al.

Ingår i Annals of Oncology, s. 1383-1391, 2001

Differentially expressed cDNAs in PLCbeta3-induced tumor suppression in a human endocrine pancreatic tumor cell line: activation of the human mismatch repair protein 3 gene.

Stålberg, P; Lopez-Egido, J R; Wang, S; Gobl, A et al.

Ingår i Biochem Biophys Res Commun, s. 227-31, 2001

Treatment with Cisplatin and Etoposide in Patients with Neuroendocrine Tumors

Fjällskog, Marie-Louise; Granberg, Dan; Welin, Staffan; Eriksson, Christoffer et al.

Ingår i Cancer, s. 1101-1107, 2001

Novel long-acting somatostatin analog with endocrine selectivity: potentsuppression of growth hormone but not of insulin.

Afargan, M; Tiensuu Janson, E; Gelerman, G; Rosenfeld, R et al.

Ingår i Endocrinology, s. 477, 2001

Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.

Oberg, K

Ingår i Ann Oncol, 2001

Standardisation of imaging in neuroendocrine tumours: results of a European delphi process.

Ricke, J; Klose, K J; Mignon, M; Oberg, K et al.

Ingår i Eur J Radiol, s. 8-17, 2001

Use of PET in neuroendocrine tumors: In vivo applications and in vitro studies

Eriksson, Barbro; Bergström, Mats; Örlefors, Håkan; Sundin, Anders et al.

Ingår i The Quarterly journal of nuclear medicine, s. 68-76, 2000

Subcellular distribution of phospholipase C isoforms in rodent pancreas and gastric mucosa

Wang, Shu; Lukinius, Agneta; Zhou, Yinghua; Stålberg, Peter et al.

Ingår i Endocrinology, s. 2589-2593, 2000

• DOI för Subcellular distribution of phospholipase C isoforms in rodent pancreas and gastric mucosa

Subcellular distribution of phospholipase C isoforms in rodent pancreas and gastric mucosa.

Wang, S; Lukinius, A; Zhou, Y; Stålberg, P et al.

Ingår i Endocrinology, s. 2589-93, 2000

Nuclear localization of 111In after intravenous injection of 111In-DTPA-D-Phe-1-octreotide to patients with neuroendocrine tumors.

Tiensuu Janson, E; Westlin, JE; Öhrvall, U; Öberg, K et al.

Ingår i J Nuclear Medicine, s. 1514, 2000

Transmembrane protein tyrosine phosphatase IA-2 (ICA512) is expressed inhuman midgut carcinoids but is not detectable in normal enterochromaffincells.

Cunningham, JL; Lopez-Egido, JR; Tiensuu Janson, E; Eriksson, B et al.

Ingår i J Endocrinol, s. 315, 2000

Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours

Larsson, Gunnel; Sjödén, Per-Olow; Öberg, Kjell; von Essen, Louise

Ingår i Annals of Oncology, s. 1321-1327, 1999

Positron emission tomography in neuroendocrine tumours

Eriksson, Barbro; Örlefors, Håkan; Sundin, Anders; Skogseid, Britt et al.

Ingår i The Italian Journal of Gastroenterology and Hepatology, 1999

Plasma Chromogranin A In Patients with Multiple Endocrine Neoplasia Type 1

Granberg, Dan; Stridsberg, Mats; Seensalu, Rein; Eriksson, Barbro et al.

Ingår i Journal of Clinical Endocrinology and Metabolism, s. 2712-2717, 1999

Increased intestinal non-substance P tachykinin concentrations in malignant midgut carcinid disease

Makridis, C; Theodorsson, E; Åkerström, Göran; Öberg, Kjell et al.

Ingår i J Gastroenterol Hepatol, s. 500-507, 1999

Somatostatin receptor ligands and their use in the treatment of endocrine disorders

Tiensuu Janson, E; Oberg, Kjell

Ingår i Curr Pharm Des, s. 693, 1999

Tumour markers in neuroendocrine tumours

Oberg, Kjell; Tiensuu Janson, E; Eriksson, undefined

Ingår i Ital J Gastroenterol Hepatol, s. 160, 1999

In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex

Lukinius, Agneta; Ohrvall, U; Westlin, Jan Eric; Oberg, Kjell et al.

Ingår i Acta Oncol., s. 383, 1999

Targeted disruption of the mouse phospholipase C β3 gene results in early embryonic lethality

Wang, Shu; Gebre-Medhin, Samuel; Betsholtz, Christer; Stålberg, Peter et al.

Ingår i FEBS Letters, s. 261-265, 1998

• DOI för Targeted disruption of the mouse phospholipase C β3 gene results in early embryonic lethality

Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization?

Skogseid, Britt; Öberg, Kjell; Åkerström, Göran; Eriksson, Barbro et al.

Ingår i World Journal of Surgery, s. 673-677; discussion 667-668, 1998

• DOI för Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization?

[PET in neuroendocrine tumors].

Eriksson, B; Örlefors, Håkan; Sundin, Anders; Westlin, J E et al.

Ingår i Nordisk Medicin, s. 308-312, 1998

Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids

Granberg, Dan; Wilander, Erik; Stridsberg, Mats; Granerus, Göran et al.

Ingår i Gut, s. 223-228, 1998

Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies.

Tiensuu Janson, E; Stridsberg, M; Gobl, A; Westlin, J E et al.

Ingår i Cancer Res, s. 2375-8, 1998

Expression of p68 protein kinase and its prognostic significance during IFN-a therapy in patients with carcinoid tumors

Zhou, Yinghua; Gobl, Anders; Wang, Shu; Jacobsen, M B et al.

Ingår i Eur J Cancer, s. 2046, 1998

Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center

Tiensuu Janson, Eva; Holmberg, Lars; Stridsberg, Mats; Eriksson, Barbro et al.

Ingår i Annals of Oncology, s. 685-690, 1997

• DOI för Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center

Induction of apoptosis in neuroendocrine tumors of digestive system during treatment with somatostatin analogs.

Imam, Hassan; Eriksson, Barbro; Lukinius, Agneta; Tiensuu Janson, Eva et al.

Ingår i Acta Oncol., s. 60714, 1997

Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors

Makridis, Charlie; Rastad, Jonas; Oberg, K; Åkerström, Göran

Ingår i World J Surg, s. 900, 1996

The use of new somatostatin analogues, lanreotide and octastatin, inneuroendocrine gastro-intestinal tumours.

Eriksson, Barbro; Tiensuu Janson, E; Bax, ND; Mignon, M et al.

Ingår i Digestion, s. 77, 1996

A comparison between the efficacy of somatostatin receptor scintigraphy and in situ hybridization for somatostatin receptor subtype 2 mRNA to predict therapeutic outcome in carcinoid patients

Tiensuu Janson, E; Gobl, Anders; Kalkner, M; Oberg, Kjell

Ingår i Cancer Research, s. 2561, 1996

Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours

Stridsberg, Mats; Eriksson, Barbro; Lundqvist, Gudmar; Skogseid, Britt et al.

Ingår i Regulatory Peptides, s. 119-131, 1995

• DOI för Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours

Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radioligand uptake and tumor markers.

Kalkner, Karl Mikael; Tiensuu Janson, Eva; Nilsson, S; Carlsson, S et al.

Ingår i Cancer Research, s. 5801, 1995

Multiple endocrine neoplasia type 1. Clinical features and screening.

Skogseid, B; Rastad, J; Oberg, K

Ingår i Endocrinol Metab Clin North Am, s. 1-18, 1994

Expression of transforming growth factor b1, b2, b3 in neuroendocrine tumors of the digestive system

Chaudhry, A; Öberg, Kjell; Gobl, Anders; Heldin, Carl-Henrik et al.

Ingår i Anticancer Res, s. 2085, 1994

Inhibition of insulin secretion, but normal peripheral insulin sensitivity, in a patient with a malignant endocrine pancreatic tumour producing high amounts of an islet amyloid polypeptide-like molecule.

Stridsberg, M; Berne, C; Sandler, S; Wilander, E et al.

Ingår i Diabetologia, s. 843-9, 1993

Fragments of chromogranin A are present in the urine of patients with carcinoid: development of a specific radioimmunoassay for chromogranin A and its fragments.

Stridsberg, M; Hellman, U; Wilander, E; Lundqvist, G et al.

Ingår i J Endocrinol, s. 329-37, 1993

Islet amyloid polypeptide-producing pancreatic islet cell tumour: A clinical and biochemical characterization

Stridsberg, M; Wilander, E; Öberg, K; Lundqvist, G et al.

Ingår i Scand. J. Gastroenterol, s. 155-159, 1992

[New medical therapy of neuroendocrine gastrointestinal tumors]

Eriksson, B; Janson, E T; Skogseid, B; Oberg, K

Ingår i Lakartidningen, s. 2668-72, 1990

Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours.

Grander, D; Oberg, K; Lundqvist, M L; Tiensuu Janson, E et al.

Ingår i Lancet, s. 337-40, 1990

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Ambrosini, Valentina; Kunikowska, Jolanta; Baudin, Eric; Bodei, Lisa et al.

Ingår i European Journal of Cancer, s. 56-73, 2021

• DOI för Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement

Niederle, Bruno; Selberherr, Andreas; Bartsch, Detlef K.; Brandi, Maria L. et al.

Ingår i Neuroendocrinology, s. 609-630, 2021

• DOI för Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement

A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood

Öberg, Kjell; Califano, A.; Strosberg, J. R.; Ma, S. et al.

Ingår i Annals of Oncology, s. 202-212, 2020

• DOI för A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood

Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy

Bodei, Lisa; Schoeder, Heiko; Baum, Richard P.; Herrmann, Ken et al.

Ingår i The Lancet Oncology, 2020

• DOI för Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy

The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors

Malczewska, Anna; Kos-Kudla, Beata; Kidd, Mark; Drozdov, Ignat et al.

Ingår i Advances in Medical Sciences, s. 18-29, 2020

• DOI för The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors
• Ladda ner fulltext (pdf) av The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors

An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis

Malczewska, Anna; Kidd, Mark; Matar, Somer; Kos-Kudla, Beata et al.

Ingår i Neuroendocrinology, s. 198-216, 2020

• DOI för An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis

Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift

Waldum, Helge L.; Öberg, Kjell; Sördal, Öystein F.; Sandvik, Arne K. et al.

Ingår i Therapeutic Advances in Gastroenterology, 2018

• DOI för Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift
• Ladda ner fulltext (pdf) av Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift

Management of functional neuroendocrine tumors of the pancreas

Öberg, Kjell

Ingår i Gland surgery, s. 20-27, 2018

• DOI för Management of functional neuroendocrine tumors of the pancreas

Medical Therapy of Gastrointestinal Neuroendocrine Tumors

Öberg, Kjell

Ingår i Visceral Medicine, s. 352-356, 2017

• DOI för Medical Therapy of Gastrointestinal Neuroendocrine Tumors

Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.

Kidd, Mark; Modlin, Irvin; Öberg, Kjell

Ingår i Nature Reviews Clinical Oncology, s. 691-705, 2016

• DOI för Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.

Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future

Öberg, Kjell; Lamberts, Steven W. J.

Ingår i Endocrine-Related Cancer, 2016

• DOI för Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future

Neuroendocrine gastro-enteropancreatic tumors - from eminence based to evidence-based medicine - A Scandinavian view

Öberg, Kjell

Ingår i Scandinavian Journal of Gastroenterology, s. 727-739, 2015

• DOI för Neuroendocrine gastro-enteropancreatic tumors - from eminence based to evidence-based medicine - A Scandinavian view

Consensus on biomarkers for neuroendocrine tumour disease

Öberg, Kjell; Modlin, Irvin M.; De Herder, Wouter; Pavel, Marianne et al.

Ingår i The Lancet Oncology, 2015

Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

Walenkamp, Annemiek; Crespo, Guillermo; Fierro Maya, Felipe; Fossmark, Reidar et al.

Ingår i Endocrine-Related Cancer, 2014

• DOI för Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges

Castano, J. P.; Sundin, Anders; Maecke, H. R.; Villabona, C. et al.

Ingår i Cancer Metastasis Review, s. 353-359, 2014

• DOI för Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges

Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches

Öberg, Kjell; Casanovas, Oriol; Castaño, Justo P; Chung, Daniel et al.

Ingår i Clinical Cancer Research, s. 2842-2849, 2013

• DOI för Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches

The genetics of neuroendocrine tumors

Öberg, Kjell

Ingår i Seminars in Oncology, s. 37-44, 2013

• DOI för The genetics of neuroendocrine tumors

Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)

Öberg, Kjell

Ingår i Theranostics, s. 448-458, 2012

• DOI för Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)

Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors

Öberg, Kjell

Ingår i Clinics, s. 109-112, 2012

• DOI för Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors

Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches

Öberg, Kjell

Ingår i Current Opinion in Oncology, 2012

• DOI för Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches

Treatment upon metastatic pancreatic Nets: Does cheomotherapy still paly a role in the area of targeted treatment?

Öberg, Kjell

Ingår i Pancreatic Disorders & Therapy, 2012

• DOI för Treatment upon metastatic pancreatic Nets: Does cheomotherapy still paly a role in the area of targeted treatment?

Current knowledge on diagnosis and staging of neuroendocrine tumors

Öberg, Kjell; Castellano, Daniel

Ingår i Cancer Metastasis Review, s. 3-7, 2011

• DOI för Current knowledge on diagnosis and staging of neuroendocrine tumors

Somatostatin analogs for the treatment of neuroendocrine tumors

Culler, Michael D.; Öberg, Kjell; Arnold, Rudolf; Krenning, Eric P. et al.

Ingår i Cancer Metastasis Review, s. 9-17, 2011

• DOI för Somatostatin analogs for the treatment of neuroendocrine tumors

Oncolytic Viruses for the Treatment of Neuroendocrine Tumors

Essand, Magnus; Leja, Justyna; Giandomenico, Valeria; Öberg, Kjell E.

Ingår i Hormone and Metabolic Research, s. 877-883, 2011

• DOI för Oncolytic Viruses for the Treatment of Neuroendocrine Tumors

Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors

Lindholm, Daniel P; Öberg, Kjell

Ingår i Hormone and Metabolic Research, s. 832-837, 2011

• DOI för Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors

Pancreatic endocrine tumors

Öberg, Kjell

Ingår i Seminars in Oncology, s. 594-618, 2010

• DOI för Pancreatic endocrine tumors

Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy

Öberg, Kjell E.; Reubi, Jean-Claude; Kwekkeboom, Dik J.; Krenning, Eric P.

Ingår i Gastroenterology, s. 742-753, 753.e1, 2010

• DOI för Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy

Somatostatin analog octreotide LAR^® in gastro–entero–pancreatic tumors

Öberg, Kjell

Ingår i Expert review of anticancer therapy, s. 557-566, 2009

• DOI för Somatostatin analog octreotide LAR^® in gastro–entero–pancreatic tumors

Gastroenteropancreatic neuroendocrine tumours

Modlin, Irvin M.; Öberg, Kjell; Chung, Daniel C.; Jensen, Robert T. et al.

Ingår i The Lancet Oncology, s. 61-72, 2008

• DOI för Gastroenteropancreatic neuroendocrine tumours

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors

Vilar, Eduardo; Salazar, Ramón; Pérez-García, Jose; Cortes, Javier et al.

Ingår i Endocrine-Related Cancer, s. 221-232, 2007

• DOI för Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors

Interferon-{alpha} and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?

Fazio, N; de Braud, F; Delle Fave, G; Öberg, Kjell

Ingår i Annals of Oncology, s. 13-19, 2007

• DOI för Interferon-{alpha} and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?

The ultimate biochemical diagnosis of endocrine pancreatic tumours in MEN-1.

Oberg, K; Skogseid, B

Ingår i J Intern Med, s. 471-6, 1998

A century of advances in neuroendocrine tumor biology and treatment: A tribute to Siegried Oberndorfer

Modlin, Irvin M; Öberg, Kjell

Felsenstein CCCP, 2007

Imaging of Neuroendocrine Tumors

Öberg, Kjell; Sundin, Anders

Ingår i Imaging in Endocrine Disorders, s. 142-151, Karger, 2016

• DOI för Imaging of Neuroendocrine Tumors

Imaging of Neuroendocrine Tumors

Öberg, Kjell; Sundin, Anders

Ingår i Imaging in Endocrine Disorders, s. 142-151, S. Karger, 2016

Tumores Neuroendocrinos Gastrointestinais:  

Öberg, Kjell E

Ingår i Aparelho Digestivo Clinica e Cirurgia, s. 337, Atheneu, 2012

Which therapy for which patient?

Öberg, Kjell

Ingår i Advances in neuroendocrine tumor management, s. 64-70, Future Medicine, 2011

Treatment strategies in neuroendocrine tumours:  

Öberg, Kjell

Ingår i Treatment Strategies Oncology, s. 117-119, Cambridge Research Centre, 2011

Neuroendocrine Tumours

Öberg, Kjell

Ingår i Management of Rare Adult Tumours, s. 539-550, Springer, 2010

Chapter 6, Diagnostic pathways:  

Öberg, Kjell; Metz, David C

Ingår i Handbook of Gastroenteropancreatic and thoracic neuroendocrine tumours, Bioscientifica, 2010

Receptor Ligands: Somatostatin analogs

Öberg, Kjell

Ingår i Bioactive Peptides, s. 169-187, CRC Press, 2009

Carcinoid Tumors

Janson, Eva Tiensuu; Öberg, Kjell

Ingår i Hematology-oncology therapy, s. 72-79, McGraw-Hill, 2007

Neuroendocrine tumours

Granberg, Dan; Öberg, Kjell

Ingår i Update on Cancer Therapeutics 2, s. 41-52, Elsevier, Oxford, 2007

Non-functioning pancreatic endocrine tumors

Öberg, Kjell; Modlin, Irvin M

Ingår i A Century of Advances in Neuroendocrine tumor biology and treatment, s. 86-99, Felsenstein, 2007

Rectal neuroendocrine tumors: Diagnosis and treatment

Modlin, Irvin; Drozdov, Ignat; Gustafsson, Björn I; Öberg, Kjell et al.

Ingår i A Century of Advances in Neuroendocrine tumor biology and treatment, s. 124-133, Felsenstein, 2007

Summation Session Section II: Neuroendocrine cell biology

Öberg, Kjell; Rehfeld, J

Ingår i A Century of Advances in Neuroendocrine tumor biology and treatment, 2007

Carcinoid tumors - current considerations

Öberg, Kjell

Ingår i A Century of Advances in Neuroendocrine tumor biology and treatment, s. 40-53, Felsenstein, 2007

Carcinoid tumors, carcinoid syndrome and related disorders

Öberg, Kjell

Ingår i Williams Textbook of Endocrinology. 11th edition, s. 1821-1840, Saunders Elsevier, 2007

Neuroendokrina buktumörer

Öberg, Kjell

Ingår i Internmedicin 4th ed, s. 681-687, Liber, Stockholm, 2006

The role of radiopharmaceuticals in diagnosis of neuroendocrine tumors

Öberg, Kjell

Ingår i 2006 ASCO Educational Book, ASCO, Virginia, 2006

Diagnostic Pathways

Öberg, Kjell

Ingår i Neuroendocrine Tumors Handbook, BioScientifica, 2006

The carcinoid syndrome

Tiensuu Janson, E; Öberg, K

Ingår i Gastroenterology and Hepatology: the Modern Clinician's Guide, s. 823-830, Weinstein WM, Hawkey CJ and Bosch J, 2005

Diseases of the gut and liver: The carcinoid syndrome

Öberg, Kjell; Tiensuu Janson, Eva

Ingår i Clinical Gastroenterology and Hepatology, s. 823, Elsevier Mosby, 2005

Carcinoid Syndrome

Öberg, Kjell; Eriksson, Barbro

Ingår i Endocrinology, Elsevier, 2005

Somatostatin analogue therapy of neuro-endocrine gastro-entero pancreatic tumors

Öberg, Kjell

Ingår i Somatostatin, s. 251-270, Kluwer Academic Publishers, 2004

PET for clinical diagnosis and research in neuroendocrine tumors

Eriksson, Barbro; Bergström, M; Örlefors, Håkan; Sundin, Anders et al.

Ingår i Diagn Nuclear Medicine 4th edition, s. 747-754, 2003

Neuroendocrine tumors

Öberg, K; Stridsberg, M

Ingår i Tumor markers, s. 339-349, 2002

Carcinoid tumors, carcinoid syndrome and related disorders

Öberg, Kjell

Ingår i Williams Textbook of Endocrinology. 10th edition, s. 1857-1876, Saunders, 2002

Malignant neuroendocrine tumors.

Tiensuu Janson, E; Oberg, K

Ingår i Cancer Chemother Biol Response Modif, s. 463, 2002

Neuroendocrine tumors: New perspection in their therapy

Eriksson, Barbro; Öberg, Kjell

Ingår i Advances in pancreatic disease, s. 376-96, Georg Thieme Verlag Stuttgart, New York, 2000

Clinical GastroenterologyCarcinoid tumours.

Tiensuu Janson, E; Oberg, K

1996

Carcinoid tumours

Tiensuu Janson, E; Oberg, K

Ingår i Clinical Gastroenterology, 1996

Nordic and North American neuro endocrine tumor management: A clinical and scientific synopsis

Modlin, Irvin; Öberg, Kjell

2008

Interferon: Does it still play a role?

Öberg, Kjell

2007

Treatment of neuroendocrine tumours of the gastrointestinal tract

Öberg, Kjell

Ingår i III Interdisciplinary Course on Oncology, 2004

Advances in Neuroendocrine Tumor Management

Öberg, Kjell E

Future Medicine Ltd, 2011

Advances in Neuroendocrine Tumor Management

Öberg, Kjell

Future Medicine Ltd, 2011

• DOI för Advances in Neuroendocrine Tumor Management

Neuroendocrine tumours

Öberg, Kjell; Eriksson, Barbro

Elsevier, 2007

How does PROMID change the treatment landscape of NET

Öberg, Kjell

2010

Neuroendocrine tumours.

Granberg, Dan; Oberg, Kjell

Ingår i Cancer Chemother Biol Response Modif, s. 471-83, 2005

Neuroendocrine GEP Tumors-Recent update on diagnosis and treatment

Oberg, Kjell

2005

The role of the somatostatin analogues

Öberg, Kjell

Ingår i NETnews, 2004

Neuroendocrine tumors-Somatostatin receptors and treatment

Tiensuu Janson, Eva; Öberg, Kjell

Ingår i Austral-Asian Journal of Cancer, s. 51-59, 2004

Tumor markers in neuroendocrine gastrointestinal tumors

Öberg, Kjell

2004